Specifically, frequencies of CD133+ lymphoid-primed multipotent progenitors (LMPP) and CD133+ granulocyte–monocyte progenitors (GMP) were significantly higher in CML-BP compared to de novo BCR::ABL1+AML (Fig. 2F, G). This evidence concerns the gene BCR and acute myeloid leukemia.